Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun 16;45(1):246.
doi: 10.1007/s10792-025-03622-2.

Safety and efficacy of a novel intense pulsed light system in patients with meibomian gland dysfunction: a randomized, double-masked, intra-individual controlled study

Andreas Schlatter  1   2 , Stefan Palkovits  3 , Sahand Amir-Asgari  1 , Manuel Ruiss  1 , Johannes Zeilinger  1 , Andreas Rotter  1 , Doreen Schmidl  2 , Oliver Findl  1
Affiliations
Randomized Controlled Trial

Safety and efficacy of a novel intense pulsed light system in patients with meibomian gland dysfunction: a randomized, double-masked, intra-individual controlled study

Andreas Schlatter et al. Int Ophthalmol. .

Abstract

Purpose: Intense pulsed light (IPL) therapy is an approach to ameliorate meibomian gland dysfunction (MGD). A novel IPL system for the treatment of MGD is the LacryStim device. The aim of this study is to investigate the safety and efficacy of the LacryStim device in patients with MGD.

Methods: This study was conducted in a prospective, randomized, intra-individual sham-controlled, double-masked design. Three treatment visits and three study visits at baseline and after three and six months were performed. The randomized study eye (SE) was treated using 8 J/cm2. The contralateral control eye (CE) was sham-treated with 1 J/cm2. The primary outcome was the mean difference of meibum quality and expressibility between SEs and CEs at the six months visit.

Results: Fifty eyes of 25 patients were included in the study. While no significant differences between both groups regarding meibum quality and expressibility could be detected at the six months visit, there was a tendency towards better expressibility in both groups after six months (SEs: - 0.4, p = 0.07; CEs: - 0.4, p = 0.04). Additionally, a significant improvement in numeric rating scale in both eyes and OSDI score (both p < 0.05) at all follow-up visits and no device-related adverse events were observed.

Conclusion: To our knowledge this is the first prospective evaluation of a novel IPL device. There was a significant amelioration of subjective complaints and a tendency towards better expressibility in both study and control eyes. An intra-individual design might compound the individual analysis of either eyes in studies investigating IPL.

Clinicaltrials: gov Identifier: NCT05089591.

Keywords: Dry eye; Intense pulsed light; Meibomian gland dysfunction; Tear film.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of the City of Vienna, Austria (EC number: 21-044-0321). Financial disclosure: OF is a scientific advisor to Carl Zeiss Meditec AG, Croma and Johnson&Johnson. For the remaining authors none were declared. Consent to participate: Informed consent was obtained from all individual participants included in the study.

References

    1. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F et al (2017) TFOS DEWS II epidemiology report. Ocul Surf 15(3):334–365 - PubMed - DOI
    1. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX et al (2017) TFOS DEWS II management and therapy report. Ocul Surf 15(3):575–628 - PubMed - DOI
    1. Alghamdi YA, Camp A, Feuer W, Karp CL, Wellik S, Galor A (2017) Compliance and subjective patient responses to eyelid hygiene. Eye Contact Lens 43(4):213–217 - PubMed - PMC - DOI
    1. Chuckpaiwong V, Nonpassopon M, Lekhanont K, Udomwong W, Phimpho P, Cheewaruangroj N (2022) Compliance with lid hygiene in patients with meibomian gland dysfunction. Clin Ophthalmol 16:1173–1182 - PubMed - PMC - DOI
    1. Lane SS, DuBiner HB, Epstein RJ, Ernest PH, Greiner JV, Hardten DR et al (2012) A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea 31(4):396–404 - PubMed - DOI

Publication types

Associated data

LinkOut - more resources